{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:34Z","timestamp":1791644614613,"version":"4.3.4"},"reference-count":26,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background and aims: the side effects of immune checkpoint inhibitors (ICI) pose a problem for the clinical management of cancer patients. There is a lack of knowledge of the value of liver biopsy in patients with ICI-related drug-induced liver injury (ICI-DILI). The aim of this study was to explore the impact of liver biopsy on clinical management and response to corticosteroids, according to histological findings. Methods: We conducted a retrospective, single-center study to evaluate the biochemical, histological and clinical data of 35 patients with ICI-DILI between 2015 and 2021 in a university hospital in France. Results: Of the 35 patients with ICI-DILI (median [interquartile range] age 62 [48\u201373] years, 40% males) studied, 20 underwent a liver biopsy. There was no difference in the management of ICI-DILI according to liver biopsy in terms of ICI withdrawal, reduction or rechallenge. According to the histological profile, patients with toxic and granulomatous profiles had a better response to corticosteroids, while patients with cholangitic lesions had the worst response. Conclusion: In ICI-DILI, liver biopsy must not delay patient care but may be useful in identifying patients with a cholangitic profile who have a poorer response to corticosteroids.<\/jats:p>","DOI":"10.3390\/jcm12113751","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T02:04:21Z","timestamp":1685412261000},"page":"3751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Lucia","family":"Parlati","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennie","family":"Marcin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3571-7277","authenticated-orcid":false,"given":"Benoit","family":"Terris","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU IMAGINA, Service de Pathologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Vallet-Pichard","sequence":"additional","affiliation":[{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Corouge","sequence":"additional","affiliation":[{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Hollande","sequence":"additional","affiliation":[{"name":"Liver Cancer Unit, AP-HP, H\u00f4pital Beaujon, F-92110 Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-9201","authenticated-orcid":false,"given":"Vincent","family":"Mallet","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Cochin Site, 24 rue du Faubourg Saint-Jacques, F-75006 Paris, France"},{"name":"AP-HP. Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et Sp\u00e9cialit\u00e9s M\u00e9dico-Chirurgicales, Service d\u2019H\u00e9patologie, F-75014 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","article-title":"PD-1 Blockers","volume":"162","author":"Wolchok","year":"2015","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"Michot","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to admin-istration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","article-title":"Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis","volume":"64","author":"Kumar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clin-ical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for di-agnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune check-point inhibitor (ICI) colitis and hepatitis: Expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibi-tor Hepatitis in Patients with Cancer","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","unstructured":"(2023, May 02). Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_12","unstructured":"(2022, May 28). Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"Michot","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.annpat.2018.07.005","article-title":"Hepatic and Digestive Adverse Events of Immune Checkpoint Inhibitors (An-ti-CTLA-4 and, Anti-PD-1\/pd-L1): A Clinico-Pathological Review","volume":"38","author":"Papouin","year":"2018","journal-title":"Ann. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepato-toxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: A systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100719","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","article-title":"Occurrence and number of immune-related adverse events are independently asso-ciated with survival in advanced non-small-cell lung cancer treated by nivolumab","volume":"107","author":"Bouhlel","year":"2020","journal-title":"Bull. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with Immune Checkpoint Inhibitors after a Severe Immune-Related Hepatitis: Results from a Prospective Multicenter Study","volume":"21","author":"Salcedo","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:44:29Z","timestamp":1760125469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113751"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113751","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]}}}